
Novel therapy for ischaemia with no obstructive coronary arteries
Coronary vascular dysfunction causes microvascular angina and vasospastic angina, which are prevalent clinical endotypes of myocardial ischaemia with no obstructive coronary arteries (INOCA). INOCA impairs quality of life and confers an increased likelihood of cardiovascular events and health resource utilization.
Contemporary advances in non-invasive and invasive testing facilitate an accurate diagnosis and linked therapy. New guideline recommendations and patient advocacy are also relevant. Nonetheless, a lack of disease-modifying therapy for INOCA perpetuates the medical need.



